普萘洛尔与美托洛尔治疗ICD患者电风暴的比较
本研究为随机对照试验,纳入60例ICD患者,比较普萘洛尔(160 mg/24 h)与美托洛尔(200 mg/24 h)联合静脉胺碘酮治疗电风暴的疗效。结果显示普萘洛尔组室性心律失常事件发生率降低2.67倍,ICD放电率降低2.34倍,且心律失常终止时间及住院时间更短。
要点
- 普萘洛尔联合静脉胺碘酮优于美托洛尔联合胺碘酮,可显著减少ICD患者电风暴复发。
- 普萘洛尔组24小时内无心律失常事件比例达90.0%,高于美托洛尔组的53.3%。
- 普萘洛尔组心律失常终止可能性更高(美托洛尔组风险比0.225),住院时间更短。
核心结论
- 静脉胺碘酮联合口服普萘洛尔治疗ICD患者电风暴安全有效,且优于联合口服美托洛尔。
研究设计与样本
- 2011至2016年随机对照试验,纳入60例ICD患者(45男,平均年龄65.0±8.5岁),电风暴发生于入院24小时内。
- 患者随机接受普萘洛尔160 mg/24 h(A组)或美托洛尔200 mg/24 h(B组),均联合静脉胺碘酮48小时。
主要发现
- 普萘洛尔组相比美托洛尔组,室性心律失常事件发生率比为0.375(95%CI 0.207-0.678,p=0.001),ICD放电率比为0.428(95%CI 0.227-0.892,p=0.004),校正年龄、性别、射血分数、NYHA分级、心衰类型、心律失常类型及入ICU前心律失常事件。
- 治疗24小时后,A组27/30(90.0%)无心律失常事件,B组16/30(53.3%),p=0.03。
- 美托洛尔组相比普萘洛尔组,心律失常终止的可能性降低77.5%(风险比0.225,95%CI 0.112-0.453,p<0.001)。
- 普萘洛尔组心律失常终止时间和住院时间均显著更短(p<0.05)。
临床怎么用
- 对于ICD患者发生电风暴,可考虑静脉胺碘酮联合口服普萘洛尔(160 mg/24 h)治疗,可能优于联合美托洛尔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electrical storm (ES), characterized by unrelenting recurrences of ventricular arrhythmias, is observed in approximately 30% of patients with implantable cardioverter-defibrillators (ICDs) and is associated with high mortality rates. OBJECTIVES: Sympathetic blockade with β-blockers, usually in combination with intravenous (IV) amiodarone, have proved highly effective in the suppression of ES. In this study, we compared the efficacy of a nonselective β-blocker (propranolol) versus a β1-selective blocker (metoprolol) in the management of ES. METHODS: Between 2011 and 2016, 60 ICD patients (45 men, mean age 65.0 ± 8.5 years) with ES developed within 24 h from admission were randomly assigned to therapy with either propranolol (160 mg/24 h, Group A) or metoprolol (200 mg/24 h, Group B), combined with IV amiodarone for 48 h. RESULTS: Patients under propranolol therapy in comparison with metoprolol-treated individuals presented a 2.67 times decreased incidence rate (incidence rate ratio: 0.375; 95% confidence interval: 0.207 to 0.678; p = 0.001) of ventricular arrhythmic events (tachycardia or fibrillation) and a 2.34 times decreased rate of ICD discharges (incidence rate ratio: 0.428; 95% CI: 0.227 to 0.892; p = 0.004) during the intensive care unit (ICU) stay, after adjusting for age, sex, ejection fraction, New York Heart Association functional class, heart failure type, arrhythmia type, and arrhythmic events before ICU admission. At the end of the first 24-h treatment period, 27 of 30 (90.0%) patients in group A, while only 16 of 30 (53.3%) patients in group B were free of arrhythmic events (p = 0.03). The termination of arrhythmic events was 77.5% less likely in Group B compared with Group A (hazard ratio: 0.225; 95% CI: 0.112 to 0.453; p < 0.001). Time to arrhythmia termination and length of hospital stay were significantly shorter in the propranolol group (p < 0.05 for both). CONCLUSIONS: The combination of IV amiodarone and oral propranolol is safe, effective, and superior to the combination of IV amiodarone and oral metoprolol in the management of ES in ICD patients.
引用
- Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. J Am Coll Cardiol. 2018. PMID: 29699616. doi:10.1016/j.jacc.2018.02.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。